Delix Therapeutics

Clinical-stage biotech company Delix Therapeutics announced the initial cohort of its first-in-human Phase 1 trial assessing the safety and efficacy of a new non-hallucinogenic, MDMA and 5-MeO-DMT inspired psychoplastogen has successfully been dosed. Taking place in the Netherlands-based CHRD with...

Delix Therapeutics, a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, received regulatory approval and is set to commence recruitment for a Phase 1 clinical trial on its non-hallucinogenic psychoplastogen lead drug candidate...

Delix Therapeutics recently published findings from a study about the mechanism that causes psychoplastogens and serotonin to activate the 5-HT2A receptor in different ways.  The paper, developed in collaboration with researchers at UC-Davis, offers unprecedented insight into the long-standing...

Delix Nabs 2 New Partners Neuroscience company Delix Therapeutics is partnering with Sweden-based Cellectricon and New York-based Expressive Neuroscience. The goal is to expedite Delix's drug development pipeline. Delix's compounds consist of small molecules capable of rapidly inducing...

Numinus Updates On New Acquisition’s Integration And Provides Client Financing Options Numinus Wellness Inc. (OTCQX: NUMIF) recently acquired psychedelics company Novamind and is successfully integrating its activities: US clinics performed solidly while client appointments grew during...

New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) published encouraging data from a Phase II trial looking at ketamine-assisted therapy for the treatment of alcohol use disorder. The company purchased the rights to the trial, which...

Delix Therapeutics, a neuroscience company developing novel therapeutics for psychiatric and neurological conditions, announced Monday that it has raised over $30 million in a convertible note financing.  The fundraising round was led by existing investors, but also added new long-...

The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics to study a non-hallucinogenic version of the psychedelic drug ibogaine.   Collaboration with the National Institute...

The Week In Psychedelics: Delix Therapeutics Closes $70 million Series A  Elon Musk Acknowledges The Therapeutic Potential Of Psychedelic MindCure Launches “Desire Project” Looking At MDMA For Female Sexual Dysfunction Braxia Publishes Results Of Clinical Trial On...

Delix Therapeutics, a drug development company in the psychedelics space, has closed a $70 million Series A financing round. The Boston-based company became known in the medicinal psychedelics space for developing a subset of psychedelic molecules that could have some of the therapeutic effects of...